Macropore Inc. IR-Pages
MacroPore Biosurgery Inc. english
New Member of the Board of Directors: E. Carmack Holmes, Surgeon-in-Chief UCLA
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
New Member of the Board of Directors: E. Carmack Holmes, Surgeon-in-Chief UCLA
MacroPore Biosurgery Appoints E. Carmack Holmes, MD, Surgeon-in-Chief of UCLA
Medical Center, to Board of Directors
San Diego / Königstein,Ts, August 14, 2003. MacroPore Biosurgery, Inc.
(Frankfurt Stock Exchange: XMP) today announced that E. Carmack Holmes, MD, has
been appointed to the company’s Board of Directors. Dr. Holmes is the Surgeon-
in-Chief of the University of California Los Angeles (UCLA) Medical Center and
holds the positions of William P. Longmire, Jr. Professor and Chairman,
Department of Surgery, UCLA School of Medicine. In 2003, UCLA Medical Center was
ranked the third best medical center in the US, according to US News and World
Report.
MacroPore Biosurgery, Inc. is a leader in the design, development, and
production of bioresorbable polymer implants for use in a variety of surgical
applications and is pioneering advancement of regenerative medicine for surgical
therapies using adult stem cells derived from adipose (fat tissue). Some
products designed for use in spine, neurosurgical, and musculoskeletal surgeries
are distributed by Medtronic, while other products designed for soft tissue are
distributed through our direct US sales force and an international distribution
network. MacroPore Biosurgery is traded on the Frankfurt Stock Exchange in
Germany under the symbol ‘XMP’. For further information please visit the web
site www.macropore.com.
end of ad-hoc-announcement (c)DGAP 14.08.2003
Issuer’s information/explanatory remarks concerning this ad-hoc-announcement:
“Dr. Holmes is a renowned thoracic surgeon and an academic leader in American
surgery. As we move our regenerative technology from concept to clinic, he will
provide the company with unique insights and experiences that will help us
provide effective therapies for doctors and their patients,” stated Marshall G.
Cox, MacroPore Biosurgery, Chairman of the Board of Directors. “He brings our
Board extensive knowledge and perspective of medical/surgical technology which
will greatly aid the Board in formulating strategies for the further development
and growth of our Company.”
“We now have promising data suggesting a therapeutic role for our proprietary
cell therapy technology for the treatment of acute myocardial infarction,”
commented Marc H. Hedrick, MD, Chief Scientific Officer. “Cardiovascular disease
accounts for a large portion of the human suffering and death world-wide, and
the treatment of this disease is a multi-billion dollar market opportunity.” Dr.
Hedrick continued, “Dr. Holmes’ expertise will be valuable as we continue to
pioneer and pursue commercialization of these types of regenerative technologies
for cardiovascular and other surgical applications.”
Dr. Holmes graduated from Duke University and holds an MD from the University of
North Carolina Medical School. His surgical training was conducted at Johns
Hopkins University and the National Cancer Institute at the National Institutes
of Health (NIH). He joined UCLA in 1973 and has held professorial positions in
the Divisions of Cardiothoracic Surgery and Surgical Oncology for over 30 years.
He served as Vice-Chairman for five years prior to holding the positions of
Chairman and Surgeon-in-Chief for the past ten years. Dr. Holmes is the
recipient of numerous awards and grants and memberships include the American
Surgical Association, the American College of Surgeons and the Association for
Academic Surgeons. He has authored 250 medical publications throughout his
career and has been an internationally invited lecturer for over 25 years.
MacroPore Biosurgery Disclaimer:
This press release may contain certain ‘forward-looking statements.’ All
statements, other than statements of historical fact, that address activities,
events or developments that we intend, expect, project, believe or anticipate
will or may occur in the future are forward-looking statements. Such statements
are based upon certain assumptions and assessments made by our management in
light of their experience and their perception of historical trends, current
conditions, expected future developments and other factors they believe to be
appropriate. The forward-looking statements included in this press release are
also subject to a number of material risks and uncertainties, including but not
limited to the risks described under “Risk Factors” in the Management’s
Discussion and Analysis of Financial Conditions and Results of Operations in our
annual report filed with the United States Securities and Exchange Commission
on Form 10-K in March 2003. These risks include our status as an emerging
company, our history of losses, our reliance on Medtronic to distribute our
products, our recent strategic decisions which change our risk profile, and
difficulties maintaining trade secrets and obtaining patent protection for our
products. We encourage you to read those descriptions carefully. We caution
investors not to place undue reliance on the forward-looking statements
contained in this press release. These statements, like all statements in this
press release, speak only as of the date of this release (unless another date is
indicated) and we undertake no obligation to update or revise the statements
except as required by law. Such forward-looking statements are not guarantees
of future performance and actual results will likely differ, perhaps materially,
from those suggested by such forward-looking statements.
——————————————————————————–
WKN: 940682; ISIN: USU553961025; Index: NEMAX 50
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart
141604 Aug 03
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden